최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Gene therapy, v.13 no.4, 2006년, pp.330 - 338
Kim, C-Y (1Research Laboratories of Dong-A Pharmaceutical Co., Ltd, Kyunggi-Do, Korea) , Jeong, M (1Research Laboratories of Dong-A Pharmaceutical Co., Ltd, Kyunggi-Do, Korea) , Mushiake, H (1Research Laboratories of Dong-A Pharmaceutical Co., Ltd, Kyunggi-Do, Korea) , Kim, B-M (1Research Laboratories of Dong-A Pharmaceutical Co., Ltd, Kyunggi-Do, Korea) , Kim, W-B (1Research Laboratories of Dong-A Pharmaceutical Co., Ltd, Kyunggi-Do, Korea) , Ko, J P (2Genenmed Inc., Jongno-Gu, Seoul, Korea) , Kim, M-H (3Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA) , Kim, M (3Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA) , Kim, T-H (4Research Center for Resistant Cells and Department of Biochemistry, Chosun University School of Medicine, Dong-Gu, Gwangju, Korea) , Robbins, P D (5Department of Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA) , Billiar, T R (3Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA) , Seol, D-W (3Department of Surgery, University of Pitts)
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), a member of the TNF family, is a type II transmembrane cytokine molecule. Soluble TRAIL has been shown to induce apoptosis in a wide variety of cancer cells in vitro and to suppress tumor growth specifically without damaging norm...
Science A Ashkenazi 281 1305 1998 10.1126/science.281.5381.1305 Ashkenazi A, Dixit VM . Death receptors: signaling and modulation. Science 1998; 281: 1305-1308.
Cell S Nagata 88 355 1997 10.1016/S0092-8674(00)81874-7 Nagata S . Apoptosis by death factor. Cell 1997; 88: 355-365.
Cell GS Salvesen 91 443 1997 10.1016/S0092-8674(00)80430-4 Salvesen GS, Dixit VM . Caspases: intracellular signaling by proteolysis. Cell 1997; 91: 443-446.
J Biol Chem M MacFarlane 272 25417 1997 10.1074/jbc.272.41.25417 MacFarlane M, Ahmad M, Srinivasula SM, Fernandes-Alnemri T, Cohen GM, Alnemri ES . Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem 1997; 272: 25417-25420.
Science G Pan 276 111 1997 10.1126/science.276.5309.111 Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J et al. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276: 111-113.
Science JP Sheridan 277 818 1997 10.1126/science.277.5327.818 Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997; 277: 818-821.
Cell H Hsu 81 495 1995 10.1016/0092-8674(95)90070-5 Hsu H, Xiong J, Goeddel DV . The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell 1995; 81: 495-504.
Cell H Hsu 84 299 1996 10.1016/S0092-8674(00)80984-8 Hsu H, Shu HB, Pan MG, Goeddel DV . TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 1996; 84: 299-308.
Cell ZG Liu 87 565 1996 10.1016/S0092-8674(00)81375-6 Liu ZG, Hsu H, Goeddel DV, Karin M . Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell 1996; 87: 565-576.
Immunity MA Kelliher 8 297 1998 10.1016/S1074-7613(00)80535-X Kelliher MA, Grimm S, Ishida Y, Kuo F, Stanger BZ, Leder P . The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. Immunity 1998; 8: 297-303.
J Biol Chem MP Boldin 270 7795 1995 10.1074/jbc.270.14.7795 Boldin MP, Varfolomeev EE, Pancer Z, Mett IL, Camonis JH, Wallach D . A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J Biol Chem 1995; 270: 7795-7798.
Cell AM Chinnaiyan 81 505 1995 10.1016/0092-8674(95)90071-3 Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM . FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995; 81: 505-512.
J Biol Chem AM Chinnaiyan 271 4961 1996 10.1074/jbc.271.9.4961 Chinnaiyan AM, Tepper CG, Seldin MF, O'Rourke K, Kischkel FC, Hellbardt S et al. FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. J Biol Chem 1996; 271: 4961-4965.
Curr Biol P Juo 8 1001 1998 10.1016/S0960-9822(07)00420-4 Juo P, Kuo CJ, Yuan J, Blenis J . Essential requirement for caspase-8/FLICE in the initiation of the Fas-induced apoptotic cascade. Curr Biol 1998; 8: 1001-1008.
Immunity SR Wiley 3 673 1995 10.1016/1074-7613(95)90057-8 Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 673-682.
J Biol Chem RM Pitti 271 12687 1996 10.1074/jbc.271.22.12687 Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A . Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271: 12687-12690.
J Clin Invest A Ashkenazi 104 155 1999 10.1172/JCI6926 Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155-162.
Nat Med H Walczak 5 157 1999 10.1038/5517 Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157-163.
Nature J Ogasawara 364 806 1993 10.1038/364806a0 Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993; 364: 806-809.
J Exp Med PR Galle 182 1223 1995 10.1084/jem.182.5.1223 Galle PR, Hofmann WJ, Walczak H, Schaller H, Otto G, Stremmel W et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 1995; 182: 1223-1230.
Immunity SS Cha 11 253 1999 10.1016/S1074-7613(00)80100-4 Cha SS, Kim MS, Choi YH, Sung BJ, Shin NK, Shin HC et al. 2.8 A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity. Immunity 1999; 11: 253-261.
Mol Cell SG Hymowitz 4 563 1999 10.1016/S1097-2765(00)80207-5 Hymowitz SG, Christinger HW, Fuh G, Ultsch M, O'Connell M, Kelley RF et al. Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol Cell 1999; 4: 563-571.
Biochemistry SG Hymowitz 39 633 2000 10.1021/bi992242l Hymowitz SG, O'Connell MP, Ultsch MH, Hurst A, Totpal K, Ashkenazi A et al. A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry 2000; 39: 633-640.
Cancer Res DW Seol 60 3152 2000 Seol DW, Billiar TR . Cysteine 230 modulates tumor necrosis factor-related apoptosis-inducing ligand activity. Cancer Res 2000; 60: 3152-3154.
Biochem J D Trabzuni 350 Part 2 505 2000 10.1042/bj3500505 Trabzuni D, Famulski KS, Ahmad M . Functional analysis of tumour necrosis factor-alpha-related apoptosis-inducing ligand (TRAIL): cysteine-230 plays a critical role in the homotrimerization and biological activity of this novel tumoricidal cytokine. Biochem J 2000; 350 (Part 2): 505-510.
Biochem Biophys Res Commun MH Kim 321 930 2004 10.1016/j.bbrc.2004.07.046 Kim MH, Billiar TR, Seol DW . The secretable form of trimeric TRAIL, a potent inducer of apoptosis. Biochem Biophys Res Commun 2004; 321: 930-935.
Mol Ther TS Griffith 4 257 2001 10.1006/mthe.2001.0439 Griffith TS, Broghammer EL . Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus. Mol Ther 2001; 4: 257-266.
Cancer Gene Ther D Jacob 12 109 2005 10.1038/sj.cgt.7700773 Jacob D, Davis JJ, Zhang L, Zhu H, Teraishi F, Fang B . Suppression of pancreatic tumor growth in the liver by systemic administration of the TRAIL gene driven by the hTERT promoter. Cancer Gene Ther 2005; 12: 109-115.
FEBS Lett JB Denault 379 113 1996 10.1016/0014-5793(95)01487-X Denault JB, Leduc R . Furin/PACE/SPC1: a convertase involved in exocytic and endocytic processing of precursor proteins. FEBS Lett 1996; 379: 113-116.
FEBS Lett J Rieger 427 124 1998 10.1016/S0014-5793(98)00409-8 Rieger J, Naumann U, Glaser T, Ashkenazi A, Weller M . APO2 ligand: a novel lethal weapon against malignant glioma? FEBS Lett 1998; 427: 124-128.
Brain Pathol JH Song 13 539 2003 10.1111/j.1750-3639.2003.tb00484.x Song JH, Song DK, Pyrzynska B, Petruk KC, Van Meir EG, Hao C . TRAIL triggers apoptosis in human malignant glioma cells through extrinsic and intrinsic pathways. Brain Pathol 2003; 13: 539-553.
Hematol Oncol Clin N Am JB Alavi 12 617 1998 10.1016/S0889-8588(05)70011-3 Alavi JB, Eck SL . Gene therapy for malignant gliomas. Hematol Oncol Clin N Am 1998; 12: 617-629.
Biochem Biophys Res Commun W Roth 265 479 1999 10.1006/bbrc.1999.1693 Roth W, Isenmann S, Naumann U, Kugler S, Bahr M, Dichgans J et al. Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. Biochem Biophys Res Commun 1999; 265: 479-483.
Surg Oncol Clin N Am DK Frank 11 589 2002 10.1016/S1055-3207(02)00021-2 Frank DK . Gene therapy for head and neck cancer. Surg Oncol Clin N Am 2002; 11: 589-606, vi-vii.
Drugs W Walther 60 249 2000 10.2165/00003495-200060020-00002 Walther W, Stein U . Viral vectors for gene transfer: a review of their use in the treatment of human diseases. Drugs 2000; 60: 249-271.
J Immunol TS Griffith 165 2886 2000 10.4049/jimmunol.165.5.2886 Griffith TS, Anderson RD, Davidson BL, Williams RD, Ratliff TL . Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J Immunol 2000; 165: 2886-2894.
Hum Gene Ther SL Eck 12 97 2001 10.1089/104303401451013 Eck SL, Alavi JB, Judy K, Phillips P, Alavi A, Hackney D et al. Treatment of recurrent or progressive malignant glioma with a recombinant adenovirus expressing human interferon-beta (H5.010CMVhIFN-beta): a phase I trial. Hum Gene Ther 2001; 12: 97-113.
Mol Ther H Zhu 9 666 2004 10.1016/j.ymthe.2004.02.007 Zhu H, Zhang L, Huang X, Davis JJ, Jacob DA, Teraishi F et al. Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms. Mol Ther 2004; 9: 666-673.
J Virol S Hardy 71 1842 1997 10.1128/jvi.71.3.1842-1849.1997 Hardy S, Kitamura M, Harris-Stansil T, Dai Y, Phipps ML . Construction of adenovirus vectors through Cre-lox recombination. J Virol 1997; 71: 1842-1849.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
출판사/학술단체 등이 한시적으로 특별한 프로모션 또는 일정기간 경과 후 접근을 허용하여, 출판사/학술단체 등의 사이트에서 이용 가능한 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.